Dronedarone Hydrochloride
FDA-approved product (tablet, oral), marketed as Dronedarone Hydrochloride, Multaq.
- Registered studies
- 2
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Atrial fibrillation
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Antiarrhythmics, class iii
- FDA pharmacologic class
- Antiarrhythmic FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA43.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli40.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae32.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis63.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
2registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Dronedarone Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- PimozideExisting use: Psychosis, Tics, Tourette syndrome55.1% AI-predicted activityagainst E. coli15 registered studies
- VenetoclaxExisting use: Cancer, Chronic lymphocytic leukemia, Neoplasm55.0% AI-predicted activityagainst E. coli50+ registered studies
- RepotrectinibExisting use: Cancer, Neoplasm55.0% AI-predicted activityagainst E. coli17 registered studies
- Telotristat EtiprateExisting use: Carcinoid tumor, Diarrhea, Neuroendocrine neoplasm54.9% AI-predicted activityagainst E. coli27 registered studies
- Prasugrel HydrochlorideExisting use: Acute coronary syndrome, Hemorrhage, Intermediate coronary syndrome and 1 more54.8% AI-predicted activityagainst E. coli50+ registered studies
- Bosutinib MonohydrateExisting use: Chronic myelogenous leukemia, Myeloid leukemia54.6% AI-predicted activityagainst E. coli2 registered studies
- Ribociclib SuccinateExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 1 more54.5% AI-predicted activityagainst E. coli1 registered study
- Ergoloid MesylatesExisting use: Cardiovascular disease54.5% AI-predicted activityagainst E. coli2 registered studies
- CabotegravirExisting use: HIV infection, HIV-1 infection, Viral disease54.4% AI-predicted activityagainst E. coli50+ registered studies
- RisperidoneExisting use: Aggressive behavior, Autism, Bipolar disorder and 4 more54.2% AI-predicted activityagainst E. coli50+ registered studies
- LorlatinibExisting use: Cancer, Lymphoma, Neoplasm and 1 more54.1% AI-predicted activityagainst E. coli50+ registered studies
- TelaprevirExisting use: Chronic hepatitis C virus infection, Viral disease53.9% AI-predicted activityagainst E. coli50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Bioequivalence Study of Dronedarone Hydrochloride Tablets in Healthy Subjects Under Fasting Conditions
NCT07396506 · start 2023-06-05
Registered record
- Registry ID
- NCT07396506
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- Dronedarone Hydrochloride Tablets; MULTAQ® (Dronedarone Hydrochloride Tablets)
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2023-06-05
- Completion
- 2023-07-10
- Enrolment
- 51
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAtrial Fibrillation (AF)InterventionDronedarone Hydrochloride Tablets; MULTAQ® (Dronedarone Hydrochloride Tablets)PhaseNot applicableRegistry statusCompletedBioequivalence Study of Dronedarone Hydrochloride Tablets
NCT07396519 · start 2022-11-14
Registered record
- Registry ID
- NCT07396519
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- Dronedarone Hydrochloride Tablets; MULTAQ® (Dronedarone Hydrochloride Tablets)
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2022-11-14
- Completion
- 2022-12-07
- Enrolment
- 48
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAtrial Fibrillation (AF)InterventionDronedarone Hydrochloride Tablets; MULTAQ® (Dronedarone Hydrochloride Tablets)PhaseNot applicableRegistry statusCompleted